DTC Rx Drug Ad Study No. 30: Do Market Claims Impact Perception?

FDA to assess whether claims such as '#1 prescribed' affect consumer views of drug product; project to cost $529,742. Chart notes price tag for 18 other DTC studies.

Do print ads touting a prescription drug as “new” or “#1 prescribed” impact consumer perceptions of a product? That’s the question FDA aims to answer in its latest study of direct-to-consumer Rx drug advertising.

The study, “Market Claims in Direct-to-Consumer Prescription Drug Print Ads,” will assess the impact of market claims on perceptions with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Podium Policy Returns To US FDA, Or Is It Podcast Policy?

20 Jun 2025

• By Michael McCaughan

US FDA critics have long decried the practice of using informal communications to convey regulatory expectations as podium policy. In the Makary era, the phrase may need to be updated because the agency now seems to be specializing in policy by podcast.

US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

20 Jun 2025

• By Cathy Kelly

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.

Branch Chief Vijay Kumar Named Acting Head Of US FDA’s Cell, Gene Therapy Office

20 Jun 2025

• By Derrick Gingery

Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.